Bryn Mawr Capital Management Inc’s Meridian Bioscience Inc VIVO Stock Holding History

Bryn Mawr Capital Management Inc’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-22,617	Closed	-$387K	–	329
2015 Q3	$387K	Buy	22,617 +5,319	+31%	+$97.2K	0.07%	322
2015 Q2	$322K	Sell	17,298 -9,370	-35%	-$174K	0.05%	363
2015 Q1	$509K	Buy	26,668 +2,758	+12%	+$51K	0.07%	248
2014 Q4	$394K	Buy	+23,910	New	+$410K	0.05%	310
2014 Q3	–	Sell	-20,138	Closed	-$416K	–	682
2014 Q2	$416K	Sell	20,138 -6,732	-25%	-$138K	0.04%	431
2014 Q1	$585K	Buy	26,870 +11,131	+71%	+$255K	0.05%	297
2013 Q4	$418K	Buy	+15,739	New	+$387K	0.03%	394
2013 Q3	–	Sell	-12,369	Closed	-$266K	–	642
2013 Q2	$266K	Buy	+12,369	New	+$267K	0.02%	381

Other funds holding VIVO

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Bryn Mawr Capital Management Inc's VIVO Position: Q4 2015 in Review

Bryn Mawr Capital Management Inc sold out of Meridian Bioscience Inc (VIVO) in Q4 2015, closing a stake of 22,617 shares — an estimated $387K sold.

Bryn Mawr Capital Management Inc first reported a position in VIVO in Q2 2013 and held it in 8 quarters. The position peaked at $585K in Q1 2014. 176 funds tracked by Wall St. Rank hold VIVO as of Q4 2015.

Bryn Mawr Capital Management Inc reported no remaining Meridian Bioscience Inc position as of Q4 2015 after selling out during the quarter.
Bryn Mawr Capital Management Inc sold 22,617 Meridian Bioscience Inc shares in Q4 2015, an estimated $387K.
Bryn Mawr Capital Management Inc first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 8 quarters.
Bryn Mawr Capital Management Inc's Meridian Bioscience Inc position peaked at $585K in Q1 2014.
176 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q4 2015.

Based on Bryn Mawr Capital Management Inc's 13F filing for Q4 2015.